Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PPRS

- PMLiVE

England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right

Simon Stevens calls for 'fair prices' from companies

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

- PMLiVE

Spinraza managed access deal in England breaks deadlock for Biogen

Patient groups remain wary, call for changes to NICE

- PMLiVE

Novartis and Sanofi heads take on UK pharma leadership roles

Sector must fight for best Brexit outcome

- PMLiVE

England opens new NHS ‘front door’ to health innovators

An upgrade to existing ACC initiative

The Orkambi row explained

Q&A and timeline

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

Pressure will be maintained on costs, despite VPAS price cap deal

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links